Kopran Limited announced its audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. In the consolidated results, revenue from operations was Rs. 23,401.83 Lakhs for the quarter ended March 31, 2026, compared to Rs. 19,427.98 Lakhs for the previous quarter (Dec 31, 2025) and Rs. 17,236.31 Lakhs for the corresponding quarter of the previous year (March 31, 2025). The consolidated results for the quarter ended March 31, 2026, show an increase of 20.45% in revenue quarter-over-quarter (QoQ) and a 35.77% increase year-over-year (YoY).

Export to Sheets

Kopran Limited, a part of the Parijat Group and promoted by the Mumbai-based Somani family, is a diversified pharmaceutical company engaged in the manufacturing of finished dosage forms and Active Pharmaceutical Ingredients (APIs). With over 60 years of expertise, the company has established a presence in over 60 countries, including nations in Africa, South Africa, the United States, Latin America, Southeast Asia, the European Union, China, Australia, and the United Kingdom. In 2025, Kopran continued its focus on growth through an integrated approach to product development, the adoption of the latest technologies, and adherence to high manufacturing standards. Notably, in 2025, the company’s board approved a Scheme of Amalgamation (merger by absorption) between Kopran Laboratories Limited (transferor) and Kopran Limited (transferee).

The company’s performance has been supported by experienced promoters and long-standing relationships with key stakeholders across various global geographies. As of September 2025, institutional holders held a significant portion of the company’s shares, with entities such as Oricon Enterprises Limited (17.43%), Panorama Finvest Pvt Ltd (7.87%), and Sarvamangal Mercantile Company Limited (6.01%) among the top institutional investors.